Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - factor viii (antihaemophilic factor), von willebrand factor human - pdr+solv for soln for inj - 1000/1000 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - factor viii (antihaemophilic factor), von willebrand factor human - pdr+solv for soln for inj - 500/500 international unit - blood coagulation factors

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 1000 iu; von willebrand factor, quantity: 2400 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Ireland - English - HPRA (Health Products Regulatory Authority)

bio products laboratory limited - factor viii (antihaemophilic factor), von willebrand factor - pdr+solv for soln for inj - 250 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

bio products laboratory limited - factor viii (antihaemophilic factor), von willebrand factor - pdr+solv for soln for inj - 500 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

bio products laboratory limited - factor viii (antihaemophilic factor), von willebrand factor - pdr+solv for soln for inj - 1000 international unit - blood coagulation factors

Israel - English - Ministry of Health

medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1500 iu/dose - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

csl behring gmbh - factor viii (antihaemophilic factor) von willebrand factor - pdr+solv for soln for inj - 500iu vial international unit

Ireland - English - HPRA (Health Products Regulatory Authority)

csl behring gmbh - factor viii (antihaemophilic factor) von willebrand factor - solution for infusion - 1000iu via international unit

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - von willebrand factor human 650 [iu] in 5 ml - vonvendi [von willebrand factor (recombinant)] is a recombinant von willebrand factor (rvwf) indicated for use in adults (age 18 and older) diagnosed with von willebrand disease (vwd) for: - on-demand treatment and control of bleeding episodes. - perioperative management of bleeding. - routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe type 3 vwd receiving on-demand therapy. vonvendi is contraindicated in patients who have had life-threatening hypersensitivity reactions to vonvendi or constituents of the product (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins) [see description (11)] . risk summary adequate and well-controlled studies with vonvendi have not been conducted in pregnant women. animal developmental and reproductive toxicity studies have not been conducted with vonvendi. it is not known whether vonvendi can cause fetal harm when administered to a pregnant woman or whether it can affect reprodu